Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers
- 1 January 1992
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 36 (1) , 115-120
- https://doi.org/10.1128/aac.36.1.115
Abstract
Teicoplanin pharmacokinetics were evaluated after multiple-dose intravenous administration to healthy male volunteers by using a randomized, double-blind, parallel design. Doses of 3, 12, or 30 mg of teicoplanin per kg of body weight were administered every 24 h for 14 days as 60-min constant-rate intravenous infusions. Blood and urine samples were collected over 21 days and analyzed by a microbiological assay. Twenty-three subjects were included in the pharmacokinetic analysis. The median pharmacokinetic parameters upon multiple-dose intravenous administration of 3, 12, and 30 mg/kg included steady-state volumes of distribution of 0.94, 0.77, and 0.68 liter/kg; total clearances of 11.9, 12.0, and 13.2 ml/h/kg; and terminal disposition half-lives of 143, 166, and 96 h, respectively. Renal clearance accounted for approximately 95% of total clearance. No dose-related differences existed for teicoplanin total or renal clearance. The steady-state volume of distribution decreased significantly with increasing doses. As a result of the decrease in the volume of distribution, the terminal disposition half-life at 30 mg/kg was significantly decreased. However, the decreases in the volume of distribution and terminal disposition half-life are of limited clinical importance, since steady-state trough concentrations in serum increase in proportion to dose. Combined results of all multiple-dose studies with similar durations of sample collection indicate no dose-related differences for any pharmacokinetic parameters from 3 to 12 mg/kg. As observed in the present study, no dose-related differences exist for teicoplanin total and renal clearances from 3 to 30 mg/kg. However, at 30 mg/kg, a significant decrease in the steady-state volume of distribution is observed. As a consequence of the reduction in the volume of distribution at 30 mg/kg with no change in clearance, the terminal disposition half-life is decreased.Keywords
This publication has 16 references indexed in Scilit:
- Pharmacokinetics and Bioavailability of a New Formulation of Teicoplanin following Intravenous and Intramuscular Administration to HumansJournal of Pharmaceutical Sciences, 1991
- Clinical Pharmacokinetics of TeicoplaninClinical Pharmacokinetics, 1990
- A sensitive bioassay for teicoplanin in serum in the presence or absence of other antibioticsDiagnostic Microbiology and Infectious Disease, 1989
- Mltidose: A Multiple-Dose Simulation Program for Linear Systems Characterized by Exponential FunctionsDrug Metabolism Reviews, 1989
- In vitro activity and human pharmacokinetics of teicoplaninAntimicrobial Agents and Chemotherapy, 1984
- Pharmacokinetics of teicoplanin in man after intravenous administrationJournal of Pharmacokinetics and Biopharmaceutics, 1984
- Comparative in vitro activities of teichomycin and other antibiotics against JK diphtheroidsAntimicrobial Agents and Chemotherapy, 1983
- Effect of Altered Plasma Protein Binding on Apparent Volume of DistributionJournal of Pharmaceutical Sciences, 1979
- Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the dataJournal of Pharmacokinetics and Biopharmaceutics, 1976
- Statistical estimations in pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1974